Screener
Rigel Pharmaceuticals RIGL Single reportable segment — Employee related expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LaborAndRelatedExpense.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total Revenues | $58,818 | $53,333 |
| Less: | ||
| Employee related expenses | 21,002 | 19,538 |
| Commercial related expenses | 7,040 | 5,339 |
| Outside clinical trial related expenses | 6,927 | 4,371 |
| Cost of product sales | 4,606 | 4,409 |
| Consultants and third-party services | 4,006 | 3,409 |
| Other segment items | 3,352 | 3,494 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's single reportable segment — employee related expenses?
- Rigel Pharmaceuticals (RIGL) reported single reportable segment — employee related expenses of $21M in Q1 2026.
- What does single reportable segment — employee related expenses mean?
- Includes all compensation, benefits, and payroll-related costs associated with the workforce within the primary operating segment. Monitoring this helps assess the company's investment in human capital relative to its operational scale.
Ask your AI about Rigel Pharmaceuticals's single reportable segment — employee related expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude